Literature DB >> 22409816

Integration of HIV testing in tuberculosis drug resistance surveillance in Kazakhstan and Kenya.

E Klinkenberg1, S van den Hof, A Tursynbayeva, H Kipruto, J Wahogo, S Pak, A Kutwa, R L'Herminez.   

Abstract

In Kenya and Kazakhstan, integration of human immunodeficiency virus (HIV) testing results into the routine surveillance of multidrug-resistant tuberculosis (MDR-TB) proved feasible and useful. The integration process improved overall data quality and data validation capacity, and integrated data are a useful addition to routine cohort and treatment outcome data. Besides their importance for individual patient care, they provide trends on the association of MDR-TB and HIV in the routine programme setting. They also form a useful epidemiological basis for more specific studies, such as on nosocomial outbreaks. Whether the system itself is sensitive enough to monitor possible outbreaks needs further investigation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22409816     DOI: 10.5588/ijtld.11.0262

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  2 in total

1.  High rates of ofloxacin resistance in Mycobacterium tuberculosis among both new and previously treated patients in Tamil Nadu, South India.

Authors:  N Selvakumar; Vanaja Kumar; S Balaji; S Prabuseenivasan; R Radhakrishnan; Gomathi Sekar; V Chandrasekaran; T Kannan; Aleyamma Thomas; S Arunagiri; Puneet Dewan; Soumya Swaminathan
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

2.  Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study.

Authors:  Sanne Christine van Kampen; Aigul Tursynbayeva; Aliya Koptleuova; Zauresh Murzakhmetova; Zauresh Murzabekova; Lyazzat Bigalieva; Moldir Aubakirova; Svetlana Pak; Susan van den Hof
Journal:  PLoS One       Date:  2015-07-16       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.